Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.
相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2015
进行中（未招募）
1
33.3%
已完成
2
66.7%
暂无批准数据
- Axsome Therapeutics has acquired exclusive global rights to AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator, through the acquisition of Baergic Bio from Avenue Therapeutics. - The compound has demonstrated favorable safety and tolerability profiles in clinical studies involving over 700 patients and showed anti-convulsant effects in multiple preclinical seizure models. - Axsome plans to begin Phase 2 trial-enabling activities in 2026 for epilepsy treatment, addressing a significant unmet medical need where more than one-third of patients do not respond to current treatments. - The transaction includes milestone payments up to $79 million in sales-based milestones and tiered mid-to-high single-digit royalties on potential global net sales.
- Avenue Therapeutics expects topline data from its Phase 1b/2a trial of AJ201 for spinal and bulbar muscular atrophy around year-end 2024. - The Phase 1b/2a trial enrolled 25 patients to evaluate the safety and tolerability of AJ201 at 600 mg/day versus placebo. - Avenue Therapeutics' Q3 2024 R&D expenses increased to $2.3 million, while the company reported a net loss of $3.1 million. - Pending additional financing, Avenue plans to initiate a Phase 2a trial for BAER-101 in epilepsy and a Phase 3 safety study for IV tramadol.
